Pharmacotherapy for knee osteoarthritis: current and emerging therapies

被引:92
作者
Cao, Peihua [1 ]
Li, Yamin [1 ]
Tang, Yujin [2 ]
Ding, Changhai [1 ,3 ]
Hunter, David J. [1 ,4 ,5 ]
机构
[1] Southern Med Univ, Zhujiang Hosp, Clin Res Ctr, Guangzhou, Guangdong, Peoples R China
[2] Youjiang Med Univ Nationalities, Dept Orthped Surg, Affiliated Hosp, Baise, Guangxi, Peoples R China
[3] Univ Tasmania, Menzies Inst Med Res, Hobart, Tas, Australia
[4] Royal North Shore Hosp, Dept Rheumatol, Sydney, NSW, Australia
[5] Univ Sydney, Inst Bone & Joint Res, Kolling Inst, Sydney, NSW, Australia
关键词
Osteoarthritis; disease modification; pain; pharmacotherapy; NERVE GROWTH-FACTOR; TOPICAL DICLOFENAC SODIUM; VITAMIN-D SUPPLEMENTATION; SELECTIVE INOS INHIBITOR; MECHANISM-BASED APPROACH; POST-HOC ANALYSIS; DOUBLE-BLIND; INTRAARTICULAR SPRIFERMIN; CARTILAGE THICKNESS; STRONTIUM RANELATE;
D O I
10.1080/14656566.2020.1732924
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction: Osteoarthritis (OA) is the leading cause of pain, loss of function and disability in the elderly, with the knee being the most impactful joint affected. Currently, there is still no 'cure' in OA treatment. Areas covered: The authors review the current and emerging therapies for knee OA including traditional OA medications (oral and topical NSAIDs, acetaminophen, and opioids) and emerging treatments including disease-modifying OA drugs. The failures of agents that have been through clinical trials are also summarized. Furthermore, the authors provide their expert perspectives on the future of pharmacotherapy for knee osteoarthritis. Expert opinion: Compared to traditional OA medications, new disease-modifying OA drugs that act by reducing inflammation and increasing cartilage repair show promise to address the unmet need of disease modification. Many of these new drugs, however, are in the preclinical stage. Long-term RCTs are expected to identify the safety and efficacy of novel OA pharmacotherapy medicines.
引用
收藏
页码:797 / 809
页数:13
相关论文
共 124 条
[1]  
Al-Saeed Abdulwahed, 2011, Oman Med J, V26, P385, DOI 10.5001/omj.2011.101
[2]   Efficacy and safety of opioids for osteoarthritis: a meta-analysis of randomized controlled trials [J].
Avouac, J. ;
Gossec, L. ;
Dougados, M. .
OSTEOARTHRITIS AND CARTILAGE, 2007, 15 (08) :957-965
[3]   Naturally occurring p16Ink4a-positive cells shorten healthy lifespan [J].
Baker, Darren J. ;
Childs, Bennett G. ;
Durik, Matej ;
Wijers, Melinde E. ;
Sieben, Cynthia J. ;
Zhong, Jian ;
Saltness, Rachel A. ;
Jeganathan, Karthik B. ;
Verzosa, Grace Casaclang ;
Pezeshki, Abdulmohammad ;
Khazaie, Khashayarsha ;
Miller, Jordan D. ;
van Deursen, Jan M. .
NATURE, 2016, 530 (7589) :184-+
[4]   Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders [J].
Baker, Darren J. ;
Wijshake, Tobias ;
Tchkonia, Tamar ;
LeBrasseur, Nathan K. ;
Childs, Bennett G. ;
van de Sluis, Bart ;
Kirkland, James L. ;
van Deursen, Jan M. .
NATURE, 2011, 479 (7372) :232-U112
[5]   Risk of acute myocardial infarction with NSAIDs in real world use: bayesian meta-analysis of individual patient data [J].
Bally, Michele ;
Dendukuri, Nandini ;
Rich, Benjamin ;
Nadeau, Lyne ;
Helin-Salmivaara, Arja ;
Garbe, Edeltraut ;
Brophy, James M. .
BMJ-BRITISH MEDICAL JOURNAL, 2017, 357
[6]   OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis [J].
Bannuru, R. R. ;
Osani, M. C. ;
Vaysbrot, E. E. ;
Arden, N. K. ;
Bennell, K. ;
Bierma-Zeinstra, S. M. A. ;
Kraus, V. B. ;
Lohmander, L. S. ;
Abbott, J. H. ;
Bhandari, M. ;
Blanco, F. J. ;
Espinosa, R. ;
Haugen, I. K. ;
Lin, J. ;
Mandl, L. A. ;
Moilanen, E. ;
Nakamura, N. ;
Snyder-Mackler, L. ;
Trojian, T. ;
Underwood, M. ;
McAlindon, T. E. .
OSTEOARTHRITIS AND CARTILAGE, 2019, 27 (11) :1578-1589
[7]  
Bassiouni H, 2017, CURR RHEUMATOL REV, V13, P65, DOI 10.2174/1573397112666160404124532
[8]   The discordance between clinical and radiographic knee osteoarthritis: A systematic search and summary of the literature [J].
Bedson, John ;
Croft, Peter R. .
BMC MUSCULOSKELETAL DISORDERS, 2008, 9 (1)
[9]   Non-steroidal anti-inflammatory drugs, including cyclo-oxygenase-2 inhibitors, in ostcoarthritic knee pain: meta-analysis of randomised placebo controlled trials [J].
Bjordal, JM ;
Ljunggren, AE ;
Klovning, A ;
Slordal, L .
BMJ-BRITISH MEDICAL JOURNAL, 2004, 329 (7478) :1317-1320D
[10]   An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) [J].
Bruyere, Olivier ;
Honvo, Germain ;
Veronese, Nicola ;
Arden, Nigel K. ;
Branco, Jaime ;
Curtis, Elizabeth M. ;
Al-Daghri, Nasser M. ;
Herrero-Beaumont, Gabriel ;
Martel-Pelletier, Johanne ;
Pelletier, Jean-Pierre ;
Rannou, Francois ;
Rizzoli, Rene ;
Roth, Roland ;
Uebelhart, Daniel ;
Cooper, Cyrus ;
Reginster, Jean-Yves .
SEMINARS IN ARTHRITIS AND RHEUMATISM, 2019, 49 (03) :337-350